



Announcement Summary

Entity name

NEURIZON THERAPEUTICS LIMITED

Announcement Type

New announcement

Date of this announcement

23/12/2025

The Proposed issue is:

A standard pro rata issue (including non-renounceable or renounceable)

A placement or other type of issue

Total number of +securities proposed to be issued for a standard pro rata issue (including non-renounceable or renounceable)

ASX +security code	+Security description	Maximum Number of +securities to be issued
NUZ	ORDINARY FULLY PAID	214,315,640

Ex date

29/12/2025

+Record date

30/12/2025

Offer closing date

21/1/2026

Issue date

29/1/2026

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
NUZ	ORDINARY FULLY PAID	89,080,864

Proposed +issue date

2/1/2026

Refer to next page for full details of the announcement

For personal use only



Part 1 - Entity and announcement details

1.1 Name of +Entity

NEURIZON THERAPEUTICS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

35094006023

1.3 ASX issuer code

NUZ

1.4 The announcement is

New announcement

1.5 Date of this announcement

23/12/2025

1.6 The Proposed issue is:

A standard +pro rata issue (non-renounceable or renounceable)

A placement or other type of issue

1.6a The proposed standard +pro rata issue is:

+ Non-renounceable

For personal use only



Part 3 - Details of proposed entitlement offer issue

Part 3A - Conditions

3A.1 Do any external approvals need to be obtained or other conditions satisfied before the entitlement offer can proceed on an unconditional basis?

No

Part 3B - Offer details

+Class or classes of +securities that will participate in the proposed issue and +class or classes of +securities proposed to be issued

ASX +security code and description

NUZ : ORDINARY FULLY PAID

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?

Existing class

Will the proposed issue of this +security include an offer of attaching +securities?

No

If the entity has quoted company options, do the terms entitle option holders to participate on exercise?

Yes

Details of +securities proposed to be issued

ASX +security code and description

NUZ : ORDINARY FULLY PAID

ISIN Code (if Issuer is a foreign company and +securities do not have +CDIs issued over them)

ISIN Code for the entitlement or right to participate in a non-renounceable issue (if Issuer is foreign company and +securities do not have +CDIs issued over them)

Offer ratio (ratio to existing holdings at which the proposed +securities will be issued)

The quantity of additional +securities to be issued **For a given quantity of +securities held**

2

5



What will be done with fractional entitlements?	Maximum number of +securities proposed to be issued (subject to rounding)
Fractions rounded up to the next whole number	214,315,640

Offer price details for retail security holders

In what currency will the offer be made?	What is the offer price per +security for the retail offer?
AUD - Australian Dollar	AUD 0.08000

Oversubscription & Scale back details

Will individual +security holders be permitted to apply for more than their entitlement (i.e. to over-subscribe)?

Yes

Describe the limits on over-subscription

Eligible shareholders who take up their entitlement in full may also apply for additional new shares under the oversubscription facility.

Will a scale back be applied if the offer is over-subscribed?

Yes

Describe the scale back arrangements

To the extent that there are excess over-subscription applications, Neurizon may apply any scale back in its discretion, which may include having regard to the pro rata entitlement of eligible shareholders who apply for additional new shares.

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Details of company options where holders entitled to participate in the offer

ASX +security code and description

NUZOA : OPTION EXPIRING 30-APR-2026

Date Option must be exercised by

30/12/2025

Part 3C - Timetable

3C.1 +Record date

30/12/2025



3C.2 Ex date

29/12/2025

3C.4 Record date

30/12/2025

3C.5 Date on which offer documents will be sent to +security holders entitled to participate in the +pro rata issue

5/1/2026

3C.6 Offer closing date

21/1/2026

3C.7 Last day to extend the offer closing date

16/1/2026

3C.9 Trading in new +securities commences on a deferred settlement basis

22/1/2026

3C.11 +Issue date and last day for entity to announce results of +pro rata issue

29/1/2026

3C.12 Date trading starts on a normal T+2 basis

30/1/2026

3C.13 First settlement date of trades conducted on a +deferred settlement basis and on a normal T+2 basis

3/2/2026

Part 3E - Fees and expenses

3E.1 Will there be a lead manager or broker to the proposed offer?

Yes

3E.1a Who is the lead manager/broker?

Morgans Corporate Limited

3E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management fee of 2% (plus GST) and Selling fee of 4% (plus GST) on the Gross Proceeds of the Entitlement Offer. Where entitlements are taken up by shareholders from outside the Morgans network, Morgans will be entitled to a reduced Selling Fee of 1%. No Selling fee in relation to participation by Directors and management.

3E.2 Is the proposed offer to be underwritten?

No

3E.3 Will brokers who lodge acceptances or renunciations on behalf of eligible +security holders be paid a handling fee or commission?

No

3E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer

Standard share registry, external advisers and ASX administrative fees.



Part 3F - Further Information

3F.1 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Funds raised will be used for working capital purposes.

3F.2 Will holdings on different registers or subregisters be aggregated for the purposes of determining entitlements to the issue?

No

3F.3 Will the entity be changing its dividend/distribution policy if the proposed issue is successful?

No

3F.4 Countries in which the entity has +security holders who will not be eligible to participate in the proposed issue

Unless otherwise determined by NUZ, all countries other than Australia and New Zealand.

3F.5 Will the offer be made to eligible beneficiaries on whose behalf eligible nominees or custodians hold existing +securities

Yes

3F.5a Please provide further details of the offer to eligible beneficiaries

Nominees and custodians may not permit any beneficial shareholder to participate in the entitlement offer, in any country outside Australia and New Zealand except, with the consent of NUZ, to beneficial shareholders resident in certain other countries where NUZ may determine it is lawful and practical to make the entitlement offer.

3F.6 URL on the entity's website where investors can download information about the proposed issue

<https://investorhub.neurizon.com/>

3F.7 Any other information the entity wishes to provide about the proposed issue

Refer to NUZ's ASX announcements dated 23 December 2025.

3F.8 Will the offer of rights under the rights issue be made under a +disclosure document or product disclosure statement under Chapter 6D or Part 7.9 of the Corporations Act (as applicable)?

No

3F.9 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

For personal use only



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	13/2/2026	Estimated	

Comments

As announced on 23 December 2025 the Company has received binding commitments to raise AUD 7.1million dollars (before costs) at an issue price of 8 cents per share. Included in this amount is a total of 9,750,000 shares to be issued to Directors and Management (or their nominees) of NUZ, subject to shareholder approval at an extraordinary general meeting expected to be held in February 2026.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

NUZ : ORDINARY FULLY PAID

Number of +securities proposed to be issued

89,080,864

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?

Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.08000



Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable

7C.1 Proposed +issue date

2/1/2026

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

79,330,864 fully paid ordinary shares

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

No

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes

7E.1a Who is the lead manager/broker?

Morgans Corporate Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management fee of 2% (plus GST) and Selling fee of 4% (plus GST) on the Gross Proceeds of the Placement. No Selling fee in relation to participation by Directors and management.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

Standard share registry, external advisers and ASX administrative fees.



Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Funds raised will used to partially fund commencement of the HEALEY ALS Platform Trial.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

Refer to NUZ's ASX announcements dated 23 December 2025.

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)

For personal use only